Australia - English - Department of Health (Therapeutic Goods Administration)

advantage medical products consulting pty ltd - pitavastatin calcium, quantity: 2.09 mg (equivalent: pitavastatin, qty 2 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; triethyl citrate; aluminium magnesium silicate; magnesium stearate; lactose monohydrate; hypromellose; titanium dioxide; hyprolose - livalo is indicated as an adjunct to diet for the treatment of adult patients with primary hypercholesterolaemia, including heterozygous familial hypercholesterolaemia, when response to diet and other non-pharmacological measures is inadequate. prior to initiating therapy with livalo, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - English - Department of Health (Therapeutic Goods Administration)

advantage medical products consulting pty ltd - pitavastatin calcium, quantity: 1.045 mg (equivalent: pitavastatin, qty 1 mg) - tablet, film coated - excipient ingredients: hyprolose; titanium dioxide; triethyl citrate; hypromellose; colloidal anhydrous silica; magnesium stearate; lactose monohydrate; aluminium magnesium silicate - livalo is indicated as an adjunct to diet for the treatment of adult patients with primary hypercholesterolaemia, including heterozygous familial hypercholesterolaemia, when response to diet and other non-pharmacological measures is inadequate. prior to initiating therapy with livalo, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Canada - English - Health Canada

pharmapar inc - pravastatin sodium - tablet - 10mg - pravastatin sodium 10mg - hmg-coa reductase inhibitors

Canada - English - Health Canada

pharmapar inc - pravastatin sodium - tablet - 20mg - pravastatin sodium 20mg - hmg-coa reductase inhibitors

Canada - English - Health Canada

pharmapar inc - pravastatin sodium - tablet - 40mg - pravastatin sodium 40mg - hmg-coa reductase inhibitors

Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - pravastatin sodium - tablet - 10 milligram(s) - hmg coa reductase inhibitors; pravastatin

Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - pravastatin sodium - tablet - 40 milligram(s) - hmg coa reductase inhibitors; pravastatin

Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - pravastatin sodium - tablet - 20 milligram(s) - hmg coa reductase inhibitors; pravastatin

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pravastatin sodium, quantity: 80 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; iron oxide yellow; microcrystalline cellulose; croscarmellose sodium; magnesium stearate - as an adjunct to diet for the treatment of hypercholesterolaemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. pravastatin is indicated in patients: with previous myocardial infarction including those who have normal (4.0 to 5.5 mmol/l) serum cholesterol levels; with unstable angina pectoris (see actions, clinical trials). as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older (see actions, clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pravastatin sodium, quantity: 40 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; iron oxide yellow; brilliant blue fcf - as an adjunct to diet for the treatment of hypercholesterolaemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephritic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. patients with previous myocardial infarction including those who have normal (4.0 to 5.5 mmol / l) serum cholesterol levels. patients with unstable angina pectoris. as an adjunct to diet and lifestyle modification for the treatment of heterozygenous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older.